

Mipomersen sodium

Cat. No.:	HY-108764
CAS No.:	629167-92-6
Molecular Weight:	7595
Sequence:	DNA, d(P-thio)([2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]m5rU-[2'-O-(2-methoxyethyl)]m5rC-A-G-T-m5C-T-G-m5C-T-T-m5C-[2'-O-(2-methoxyethyl)]rG-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]rA-[2'-O-(2-methoxyethyl)]m5rC-[2'-O-(2-methoxyethyl)]m5rC), sodium salt (1:19)
Target:	HCV
Pathway:	Anti-infection
Storage:	-20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)

Mipomersen (sodium)

SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 100 mg/mL (13.17 mM; Need ultrasonic)				
		Solvent Concentration	Mass		
	Preparing Stock Solutions		1 mg	5 mg	10 mg
		1 mM	0.1317 mL	0.6583 mL	1.3167 mL
		5 mM	0.0263 mL	0.1317 mL	0.2633 mL
	10 mM	0.0132 mL	0.0658 mL	0.1317 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: PBS Solubility: 100 mg/mL (13.17 mM); Clear solution; Need ultrasonic				

BIOLOGICAL ACTIVITY

Description	Mipomersen sodium (ISIS 301012) is an antisense oligonucleotide inhibitor of apolipoprotein B (apoB). Mipomersen has anti-HCV effect and reduces the infectivity of the HCV. Mipomersen sodium can be used for the research of homozygous familial hypercholesterolemia (HoFH) ^{[1][2]} .
In Vitro	Mipomersen predominantly distributes to the liver and decreases the production of apoB-100, the primary structural protein of the atherogenic lipoproteins including low density lipoprotein (LDL), thereby reducing plasma LDL-cholesterol and apoB-100 concentrations ^[2] . Apolipoprotein (apo) B, a large amphipathic protein, plays a fundamental role in human lipoprotein metabolism. ApoB-100 is also a ligand for LDL receptor-mediated endocytosis of LDL by cells ^[2] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Philip Hair, et al. Mipomersen sodium: first global approval. *Drugs*. 2013 Apr;73(5):487-93.

[2]. Damon A Bell, et al. Mipomersen, an antisense apolipoprotein B synthesis inhibitor. *Expert Opin Investig Drugs*. 2011 Feb;20(2):265-72.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA